The first stop for professional medicines advice

Medicines planning

61 results

Applied filters

Biosimilar and key generic medicines – April 2025 update

5 March 2025An update about biosimilar and key generic medicines to support implementation with a focus on aflibercept, golimumab, nilotinib and ferric carboxymaltose.

What’s new in medicines mechanisms and governance PGDs

25 February 2025An update session for those involved in medicines governance including managing PGDs and other medicine mechanisms in practice.

Biosimilar and key generic medicines – February 2025 update

13 February 2025An update about biosimilar and key generic medicines expected in 2025/26 to support implementation across the integrated care system.

New Product Evaluations

14 November 2024A list of new product evaluations that are freely available to NHS staff.

Using our annual medicines planning publication, Prescribing Outlook

28 October 2024Users should be aware of the constraints and assumptions in creating Prescribing Outlook, as well as their responsibilities for use.

Good governance when implementing ustekinumab biosimilar

2 August 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

The licence and supporting evidence for ustekinumab biosimilars

2 August 2024Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.

Monitoring and reviewing a PGD in practice

30 July 2024Monitoring and evaluating practice under a PGD and timely review of a PGD are important steps in the development process.

Writing a PGD

30 July 2024Writing a PGD is a multi-step process, requiring input from all members of the PGD development team.

Authorising and preparing to use a PGD

30 July 2024Once a PGD is written, there are steps to be completed before the PGD is used within an organisation.